PRLD News & Events

Prelude Therapeutics files to sell 6.25M shares of common stock for holders

Prelude Therapeutics the first preclinical data on its JAK2V617F mutant selective JH2 inhibitors and additional preclinical data from its mCALR-targeted degrader antibody conjugate discovery program. Both oral presentations took place at the American Society of Hematology, ASH, 67th Annual Meeting in Orlando, FL. These presentations can be found at Publications - Prelude Therapeutics. Key highlights: First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms; PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026; First disclosure of a mutant calreticulin targeted degrader antibody conjugate with a novel CDK9 degrader payload; JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prognosis in the majority of MPN patients

At September 30, 2025, the Company had cash, cash equivalents, restricted cash and marketable securities totaling $58.2 million. Subsequent to September 30, 2025, the Company received an additional license payment from its expanded collaborative agreement with AbCellera in October 2025 and $60 million from Incyte in November 2025. Based on preliminary estimates, the Company anticipates that its existing cash, cash equivalents, restricted cash and marketable securities will fund Prelude's operations into 2027.

Reports Q3 revenue $6.5M vs. $3M last year. "Last week, we announced a number of strategic updates that significantly strengthen and shape our path forward heading into 2026," stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. "We have two promising programs advancing rapidly towards clinical development - our mutant selective JAK2V617F inhibitor program and our highly selective KAT6A degrader program. Both programs target clinically validated mechanisms in disease areas of significant unmet need for patients with clear paths to differentiation in early clinical development."